keyword
MENU ▼
Read by QxMD icon Read
search

oxybutynin

keyword
https://www.readbyqxmd.com/read/28431215/early-treatment-improves-urodynamic-prognosis-in-neurogenic-voiding-dysfunction-20-years-of-experience
#1
Lucia M Costa Monteiro, Glaura O Cruz, Juliana M Fontes, Eliane T R C Vieira, Eloá N Santos, Grace F Araújo, Eloane G Ramos
OBJECTIVE: To evaluate the association between early treatment and urodynamic improvement in pediatric and adolescent patients with neurogenic bladder. METHODOLOGY: Retrospective longitudinal and observational study (between 1990 and 2013) including patients with neurogenic bladder and myelomeningocele treated based on urodynamic results. The authors evaluated the urodynamic follow-up (bladder compliance and maximum bladder capacity and pressure) considering the first urodynamic improvement in two years as the outcome variable and early referral as the exposure variable, using a descriptive and multivariate analysis with logistic regression model...
April 18, 2017: Jornal de Pediatria
https://www.readbyqxmd.com/read/28388990/oral-oxybutynin-for-local-and-multifocal-hyperhidrosis-a-multicenter-study
#2
T Toledo-Pastrana, J Márquez-Enríquez, J F Millán-Cayetano
No abstract text is available yet for this article.
April 4, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28384267/association-between-different-anticholinergic-drugs-and-subsequent-dementia-risk-in-patients-with-diabetes-mellitus
#3
Yu-Wan Yang, Hsin-Ho Liu, Tien-Huang Lin, Hsun-Yang Chuang, Tengfu Hsieh
BACKGROUND: The effects of oxybutynin, solifenacin and tolterodine on dementia risk in patients with diabetes mellitus (DM) remain unknown. We investigated the effects of oxybutynin, solifenacin and tolterodine on dementia risk in patients with DM. METHODS: We conducted a cohort study by using the diabetes dataset of the Taiwan National Health Insurance Research Database from 1 January, 2002 to 31 December, 2013. We included 10,938 patients received one type of oxybutynin, solifenacin, or tolterodine, while 564,733 had not...
2017: PloS One
https://www.readbyqxmd.com/read/28370075/cancer-incidence-after-initiation-of-antimuscarinic-medications-for-overactive-bladder-in-the-united-kingdom-evidence-for-protopathic-bias
#4
James A Kaye, Andrea V Margulis, Joan Fortuny, Lisa J McQuay, Estel Plana, Jennifer L Bartsch, Christine L Bui, Susana Perez-Gutthann, Alejandro Arana
STUDY OBJECTIVE: To estimate the incidence of 10 common cancers among patients treated with antimuscarinic medications for overactive bladder (AMOAB). DESIGN: Retrospective cohort study. DATA SOURCE: United Kingdom's Clinical Practice Research Datalink. PATIENTS: A total of 119,912 adults with no previous cancer diagnosis who were new users of AMOABs-darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium-between January 2004 and December 2012...
March 31, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28329602/glycopyrrolate-induced-craniofacial-compensatory-hyperhidrosis-successfully-treated-with-oxybutynin-report-of-a-novel-adverse-effect-and-subsequent-successful-treatment
#5
Megan E Prouty, Ryan Fischer, Deede Liu
Hyperhidrosis, or abnormally increased sweating, is a condition that may have a primary or secondary cause. Usually medication- induced secondary hyperhidrosis manifests with generalized, rather than focal sweating. We report a 32-year-old woman with a history of palmoplantar hyperhidrosis for 15 years who presented for treatment and was prescribed oral glycopyrrolate. One month later, the palmoplantar hyperhidrosis had resolved, but she developed new persistent craniofacial sweating. After an unsuccessful trial of clonidine, oxybutynin resolved the craniofacial hyperhidrosis...
October 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28327453/combining-transcutaneous-electrical-nerve-stimulation-tens-with-oxybutynin-is-superior-to-monotherapy-in-children-with-urge-incontinence-a-randomized-placebo-controlled-study
#6
L Borch, S Hagstroem, K Kamperis, C V Siggaard, S Rittig
PURPOSE: To evaluate if combination therapy with TENS and oxybutynin results in a superior treatment response than monotherapy with the two modalities in childhood urge incontinence. MATERIALS AND METHODS: In this placebo-controlled study 66 urge incontinent children (mean age 7.3 ± 1.6 years) were randomized into three treatment groups. Group 1: active TENS + active oxybutynin (n = 22). Group 2: active TENS + placebo oxybutynin (n = 21). Group 3: active oxybutynin + placebo TENS (n = 23)...
March 18, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28300854/randomized-placebo-and-active-controlled-crossover-study-of-the-safety-and-efficacy-of-thvd-102-a-fixed-dose-combination-of-oxybutynin-and-pilocarpine-in-subjects-with-primary-focal-hyperhidrosis
#7
David M Pariser, Janakan Krishnaraja, Thomas M Tremblay, R Michael Rubison, Ted W Love, Benjamin F McGraw
BACKGROUND: While muscarinic antagonists (anticholinergics) have shown efficacy in treating primary focal hyperhidrosis (PFH), side effects - most commonly dry mouth - are intolerable for most patients. THVD-102, a fixed-dose combination product has been developed combining oxybutynin, a muscarinic antagonist, and pilocarpine, a muscarinic agonist. The pilocarpine is at a dose level and release profile optimized to correct salivary flow impaired by oxybutynin yet not interfere with the therapeutic muscarinic antagonist effect of oxybutynin upon the sweat glands...
February 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28265325/overactive-bladder-in-children
#8
REVIEW
Sophie Ramsay, Stéphane Bolduc
Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This condition is especially troublesome for pediatric patients and their families when associated with incontinence, since it negatively affects self-esteem and impairs children's development. From the patient's perspective, urgency and urge incontinence can have a significant impact, negatively affecting their quality of life. For a therapy to have true benefit, changes must not only be statistically significant, but must also be perceived as meaningful by the patient...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28260277/comparison-of-efficacy-and-tolerability-of-pharmacological-treatment-for-the-overactive-bladder-in-women-a-network-meta-analysis
#9
Sivalingam Nalliah, Pou Wg, Premjit K Masten Singh, Piravin Naidu, Vivian Lim, Arshad Asa Ahamed
BACKGROUND: Overactive bladder syndrome (OAB) is a common medical condition that causes significant distress and impact on the quality of life in women. Muscarinic receptor antagonists remain the mainstay of therapy, but they are limited by their efficacy and adverse effects. The objective of the article was to compare the clinical efficacy and tolerability of medications used to treat OAB in women through network meta-analysis. METHODS: Data from eligible studies of commonly prescribed pharmacological agents in the treatment of OAB in women were entered into Net-MetaXL after a literature search using two online databases (PubMed and Cochrane)...
March 2017: Australian Family Physician
https://www.readbyqxmd.com/read/28244893/methadone-induced-hyperhidrosis-treated-with-oxybutynin
#10
Joe Hong, Jooyeon Lee, Holly Totouom-Tangho, Norma Ramos Dunn, Ronnie Gorman Swift
OBJECTIVES: This case report aims to help healthcare providers and methadone clinic patients to recognize one of the less recognized adverse effects of methadone, hyperhidrosis, and to suggest oxybutynin as a possible solution. METHODS: A 35-year-old man on methadone maintenance therapy presented with excessive sweating, which began promptly after methadone was introduced. Urine toxicology was conducted every 2 weeks to rule out other illicit substances that may have contributed to the sweating...
February 27, 2017: Journal of Addiction Medicine
https://www.readbyqxmd.com/read/28215830/initial-urological-evaluation-and-management-of-children-with-neurogenic-bladder-due-to-myelomeningocele
#11
Cristian Sager, Carol Burek, Juan Pablo Corbetta, Santiago Weller, Javier Ruiz, Ramiro Perea, Enrique Lago, Yesica Gomez, Victor Durán, Juan Carlos López
INTRODUCTION: The proactive management of children with myelomeningocele (MMC) has contributed to decreasing their progression to end-stage renal disease, thanks to early urological evaluation and timing implementation of treatments. OBJECTIVE: To demonstrate that early urological evaluation of the urinary tract in MMC shows functional alterations in most cases, and that it requires medical intervention, even when in some cases the complementary imaging studies do not show any abnormalities...
January 30, 2017: Journal of Pediatric Urology
https://www.readbyqxmd.com/read/28196724/persistence-and-adherence-with-mirabegron-versus-antimuscarinic-agents-in-patients-with-overactive-bladder-a-retrospective-observational-study-in-uk-clinical-practice
#12
Christopher R Chapple, Jameel Nazir, Zalmai Hakimi, Sally Bowditch, Francis Fatoye, Florent Guelfucci, Amine Khemiri, Emad Siddiqui, Adrian Wagg
BACKGROUND: Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β3-adrenoceptor agonist with a different adverse event profile. OBJECTIVE: To compare persistence and adherence with mirabegron versus tolterodine extended release (ER) and other antimuscarinics in routine clinical practice over a 12-mo period. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, longitudinal, observational study of anonymised data from the UK Clinical Practice Research Datalink GOLD database...
February 11, 2017: European Urology
https://www.readbyqxmd.com/read/28120445/efficacy-and-adherence-of-flexibly-adding-on-a-second-antimuscarinic-agent-for-patients-with-refractory-overactive-bladder
#13
Chung-Cheng Wang, Yuan-Hong Jiang, Hann-Chorng Kuo
OBJECTIVES: To evaluate the efficacy and adverse events (AE) of flexibly adding on oxybutynin ER in patients with overactive bladder (OAB) refractory to monotherapy with the first muscarinic antagonist. METHODS: A total of 129 patients with refractory OAB were enrolled in a prospective, open-label protocol. Inclusion criteria were persistent symptoms or partial response to 3-month behavioral therapy and an optimized dose of one antimuscarinic agent. At baseline, weeks 4, and 12 after the oxybutynin ER (5-15 mg once a day) was flexibly added, we assessed the OAB symptom indexes and Patient Perception of Bladder Condition, uroflowmetry, and post-void residual, along with the therapeutic effect, AE, and tolerability...
January 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28120444/histopathologic-and-urodynamic-effects-of-the-anticholinergic-drugs-oxybutynin-tolterodine-and-trospium-on-the-bladder
#14
Seyfettin Orgen, Hasan Deliktas, Hayrettin Sahin, Abdullah Gedik, Yusuf Nergis
OBJECTIVES: This study aimed to evaluate the effects of intravesical instillation of the anticholinergic drugs oxybutynin, tolterodine, and trospium on bladder capacity and histopathological changes in the bladder mucosa. METHODS: The study included 20 male New Zealand white rabbits that were randomly allocated to four groups of five. In the oxybutynin, tolterodine, and trospium groups, the drugs used were 1 mg/kg of crushed tablet mixed with 5 mL of saline, instilled intravesically once per day for 4 weeks...
January 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28106275/initial-study-of-transdermal-oxybutynin-for-treating-hyperhidrosis
#15
José Francisco Millán-Cayetano, Javier Del Boz, Tomas Toledo-Pastrana, Miriam Nieto-Guindo, Pablo García-Montero, Magdalena de Troya-Martín
Oral oxybutynin for treating hyperhidrosis is effective and safe. Its side-effects are mild but frequent so we consider whether transdermal oxybutynin (considered to have a better side-effect profile) could be an alternative for treating hyperhidrosis. During 2015, a prospective study was conducted. Epidemiological variables, effectiveness (using the Hyperhidrosis Disease Severity Scale) and tolerance to transdermal oxybutynin were compiled concerning two different groups (patients previously treated or untreated with oral oxybutynin), at baseline, and at 3 and 12 months...
January 20, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28093646/mechanisms-of-inhibitory-action-of-trk-130-naltalimide-a-%C3%AE-opioid-receptor-partial-agonist-on-the-micturition-reflex
#16
Morihiro Fujimura, Naoki Izumimoto, Sayoko Kanie, Ryosuke Kobayashi, Satoru Yoshikawa, Shinobu Momen, Mikito Hirakata, Toshikazu Komagata, Satoshi Okanishi, Masashi Iwata, Tadatoshi Hashimoto, Takayuki Doi, Naoki Yoshimura, Koji Kawai
PURPOSE: To clarify the mechanism of inhibitory action of TRK-130 (Naltalimide), a unique µ-opioid receptor partial agonist, on the micturition reflex. METHODS: The effect of TRK-130 on isovolumetric rhythmic bladder contractions (RBCs) was examined in guinea pigs, the effect of which was clarified by co-treatment with naloxone or in spinal cord transection. The effect of TRK-130 on urodynamic parameters was also observed in guinea pigs. In addition, the effect of TRK-130 on bladder contraction induced by peripheral stimulation of the pelvic nerve was investigated in rats...
April 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28091711/anticholinergic-prescription-are-healthcare-professionals-the-real-burden
#17
George Araklitis, Ganesh Thiagamoorthy, Jo Hunter, Angie Rantell, Dudley Robinson, Linda Cardozo
INTRODUCTION AND HYPOTHESIS: Anticholinergic medication is the medical treatment for overactive bladder (OAB). These drugs can act on the central nervous system and can lead to cognitive decline, dementia, and potentially death. Patients taking drugs with anticholinergic effects increase their anticholinergic burden-defined as the cumulative effect of taking one or more drugs that can have adverse effects. When prescribing anticholinergic medication for the elderly, we must choose the right drug...
January 13, 2017: International Urogynecology Journal
https://www.readbyqxmd.com/read/28025920/impact-of-overactive-bladder-step-therapy-policies-on-medication-utilization-and-expenditures-among-treated-medicare-members
#18
Ibrahim M Abbass, Eleanor O Caplan, Daniel B Ng, Rita Kristy, Carol R Schermer, Pamela Bradt, Jenna M Collins, Wai Man Maria Chan, Brandon T Suehs
BACKGROUND: The impact of formulary management strategies on utilization and expenditures in overactive bladder (OAB) treatment has not been extensively investigated. In 2013, step therapy (ST) policies for 2 branded OAB treatments, mirabegron and fesoterodine, were removed from Humana Medicare Advantage Prescription Drug (MAPD) plans and Medicare prescription drug plans (PDP), allowing for an examination of the effect of ST policies on OAB medication use patterns and costs. OBJECTIVE: To assess the impact of removal of formulary restriction policies for mirabegron and fesoterodine on medication utilization patterns and costs associated with OAB treatment in Medicare patients...
January 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28001258/translation-and-validation-of-hyperhidrosis-disease-severity-scale
#19
Andrea Yasbek Monteiro Varella, Juliana Maria Fukuda, Marcelo Passos Teivelis, José Ribas Milanez DE Campos, Paulo Kauffman, Gabriel Grizzo Cucato, Pedro Puech-Leão, Nelson Wolosker
Introduction: The evaluation of patients with hyperhidrosis (HH) can be accomplished, among other ways, through questionnaires and scales. The Hyperhidrosis Disease Severity Scale (HDSS) has been used as a simple and quick tool to perform this evaluation. Although HDSS has been well established in several languages, it has not been translated into Portuguese, restricting its specific use for Brazilian patients. The aim of this study was to translate HDSS into Portuguese and validate it in a sample of Brazilian subjects...
December 2016: Revista da Associação Médica Brasileira
https://www.readbyqxmd.com/read/27976476/treatment-of-primary-hyperhidrosis-with-oral-anticholinergic-medications-a-systematic-review
#20
REVIEW
L Cruddas, D M Baker
Primary hyperhidrosis is a condition characterized by excessive sweating. Patients are treated off-license with oral anticholinergic medications and report adverse events associated with systemic anticholinergic interactions. This review assesses clinical evidence of efficacy, impact on quality of life and adverse events associated with oral anticholinergic therapy for primary hyperhidrosis. PRISMA guidelines were implemented to complete a systematic review (PROSPERO:CRD42016036326). MEDLINE, EMBASE and PubMed were searched from 1946 to 2015...
December 15, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
110797
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"